SIRDUPLA DPI (Alphapharm Pty Ltd)

SIRDUPLA DPI (powder for inhalation) is indicated for the regular treatment of asthma, where the use of a combination product is appropriate.

This may include:

• Patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids,
• Patients who are symptomatic on current inhaled corticosteroid therapy,
• Initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on 'as needed' reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day.

For the symptomatic treatment of patients with severe COPD (FEV1 less than 50 percent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta- 2 agonist bronchodilator therapy. SIRDUPLA DPI is not indicated for the initiation of bronchodilator therapy in COPD.